Join
Live feed
·
PRReleasevia Quantisnow
Longeveron Inc. logo

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2b Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (HLHS)

ByQuantisnow·Wall Street's wire, on your screen.
LGVN· Longeveron Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track LGVN (Longeveron Inc.) and more on Quantisnow.